Toca Stock Forecast 2023, 2024, 2025, 2030 | Cavix
Please disable Ad Blocker before you can visit the website !!!

Toca Stock Forecast 2023, 2024, 2025, 2030

by Cavix   ·  January 14, 2023   ·  

Toca Stock Forecast 2023, 2024, 2025, 2030

by Cavix   ·  January 14, 2023   ·  

Tocagen Inc is a clinical-stage cancer-selective gene therapy firm that aimed at developing and popularizing product candidates that engage a patient’s immune system against cancer. Its cancer-specific gene therapy technology is based on retroviral replicating vectors (RRVs), which are meant to introduce therapeutic genes into cancer cells’ DNA. Toca 511 & Toca FC, Toca stock principal product candidates, are now in Phase III clinical trials for recurrent high-grade glioma.

Toca 511 and Toca FC are also being developed in a Phase Ib clinical study for intravenous therapy of advanced malignancies. Furthermore, the firm is working on alternative RRVs that will deliver genes to cancer cells against established therapeutic targets.

The firm has a licensing agreement with ApolloBio to develop and market Toca 511 and Toca FC, as well as a partnership agreement with NRG Oncology to establish a clinical study for the treatment of patients with newly diagnosed glioblastoma using Toca 511 and Toca FC.

Where Are the Toca Headquarters?

Tocagen‘s corporate headquarters are located at 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO, CA, 92121.

Who Are Tocagen San Diego’s Key Executives?

The following individuals are members of Tocagen San Diego’s management team:

  • Martin J. Duvall, CEO & Director (Age 57)
  • Thomas E. Darcy, Co-Founder & Director (Age 68)
  • Douglas J. Jolly, Co-Founder and Exec. VP of Research & Pharmaceutical Devel. (Age 71)
  • Mark G. Foletta C.P.A., CPA, Exec. VP & CFO (Age 58)
  • Harry E. Gruber, Founder, Adviser & Director (Age 66)

Does Toca Have a Stock?

toca stock forecast


Yes. Tocagen San Diego is a stock that trades under the ticker name “NASDAQ:TOCA.”

Historical Tocagen Stock Price data:

  • NASDAQ:TOCA Market Cap (Previous Close): 6.58 M
  • Tocagen Share Volume (Previous Close): 2,795
  • Tocagen Stock Price in USD (Last): 16.450
  • 52 Week High Price of TOCA Shares: 6.77
  • 52 Week Low Price of TOCA Shares: 0.422
  • 50 Day Moving Average: 1.24
  • 200 Day Moving Average: 1.04


Toca Boca Stock raised $80 million in an initial public offering (IPO) on Thursday, April 13th, 2017. The corporation issued 7,300,000 TOCA Shares at a price range of $10.00 to $12.00 per share. Underwriters for the IPO were Leerink Partners, Evercore ISI, and Stifel.

How Much Money Does Tocagen Make?

Toca Boca Stock has a market value of $36.12 million and a profit of $40 thousand every year. Every year, the firm produces $-63.52 million in net income (profit), or ($2.69) on an earnings per share basis, according to the Tocagen Stock News.

Tocagen Stock Price Forecast

In the short term, the Toca Boca Stock is at the higher end of a very broad and downward trend, which may present a very excellent selling opportunity for the short-term investor as a response back towards the lower end of the trend may be predicted as Tocagen Stock Price Forecast experts believe.

Given the present short-term trend and TOCA Stock Price Predictions data, the TOCA Shares are anticipated to lose -34.10 percent over the next three months and, with a 90 percent likelihood, conclude the period with a TOCA Price between $0.55 and $0.86.

Please keep in mind that if the TOCA Stock Price remains at current levels or higher, Tocagen Stock Price Forecast 2022, 2023, 2024, 2025, 2030 experts’ TOCA Stock Price Predictions goal will begin to shift favorably over the following few days as the conditions for the present TOCA Stock Price Forecast is broken.

Tocagen Stock Price Forecast data:

  • 52 Week High Tocagen Stock Price Forecast: 16.338
  • 52 Week Low Tocagen Stock Price Forecast: 11.727
  • 45-Day TOCA Stock Price Predictions Moving Average: 12.621
  • 90-Day TOCA Stock Price Forecast Moving Average: 12.342
  • According to Tocagen Stock News, it is stated that the experts of Tocagen Stock Price Forecast believe that TOCA Stock Price may decline from 16.450 USD to 15.226 USD. So that, the change of negative TOCA Stock Price Predictions will be -7.440%

Is Toca Stock a Buy?

Tocagen Inc has some positive indications, but the Tocagen Stock Price Forecast experts don’t believe they are strong enough to warrant a buy recommendation. At the moment, the TOCA Stock should be considered a hold option (hold or accumulate) in this level while waiting for additional development.

Tocagen Stock News show that 2.58 million Toca Boca Shares were bought and 162.41 thousand TOCA Shares were sold in the previous 86 trades. Darcy Thomas E, who bought 500 shares 444 days ago, was the most recent trader. The big number of stocks purchased vs stocks sold indicates that insiders feel there is a significant chance of a good upside, such like positive Tocagen Stock Price Forecast data. Larger purchases in some situations can be justified by the expiration date of stock options.

Buy or Sell TOCA Stock?

Tocagen Inc‘s TOCA Shares, and perhaps its market situation, have been in a positive cycle in the previous 12 months, according to current Tocagen Stock News data (if exists). There appears to be a current pattern in which stocks in the Healthcare Health Technology sectors have been popular during this time.

Major Tocagen Stock Price Forecast experts predict a downward trend in the future and that TOCA Shares are not a viable investment for profit. Because this stock has a bad prognosis and negative TOCA Stock Price Forecast outlook, they recommend exploring for alternative ventures to construct a portfolio instead.

Trading in downturn markets is always more difficult, therefore if you are a novice, you should avoid these stocks. If you are new to trading and investment, you should always read up on the best investment techniques. If you are knowledgeable about personal finance and want to trade and invest, you may discover Tocagen Inc on the NASDAQ stock exchange (NASDAQ:TOCA).

Leave a Reply